ACADIA PHARMACEUTICALS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 17.13 USD | -0.70% |
|
+0.47% | -45.29% |
| May. 08 | Transcript : ACADIA Pharmaceuticals Inc., Q1 2024 Earnings Call, May 08, 2024 | |
| May. 08 | Earnings Flash (ACAD) ACADIA PHARMACEUTICALS Reports Q1 Revenue $205.8M, vs. Street Est of $208.6M | MT |
Presenter SpeechTazeen Ahmad (Analysts)Everybody, good afternoon. So thanks for joining us aga...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Acadia Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has a portfolio of commercial stage products, in-development product opportunities, and research programs that are designed to address unmet needs in CNS disorders and rare diseases. Its pipeline includes NUPLAZID (pimavanserin), DAYBUE (trofinetide), ACP-101, ACP-204, and Antisense Oligonucleotide (ASO) Programs. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. Trofinetide is a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 (IGF-1) designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function.
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
17.13
USD
Average target price
28.75
USD
Spread / Average Target
+67.82%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -45.29% | 2.85B | |
| +22.56% | 46.4B | |
| -1.51% | 41.75B | |
| +48.83% | 41.37B | |
| -3.42% | 29.71B | |
| +10.13% | 26.01B | |
| -20.44% | 19.52B | |
| +26.45% | 12.43B | |
| -0.14% | 12.18B | |
| -0.47% | 12.13B |
- Stock Market
- Equities
- ACAD Stock
- News ACADIA Pharmaceuticals Inc.
- Transcript : ACADIA Pharmaceuticals Inc. Presents at Bank of America 2022 Healthcare Conference, May-10-2022 03